Immunoact company information, Employees & Contact Information

Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study The Lancet

Homegrown cell, gene therapy pioneer ImmunoACT turns profitable in first year of ops The Economic Times

Startup of the year 2024- ImmunoACT BioSpectrum Asia

Caring Cross and ImmunoAdoptive Cell Therapy (ImmunoACT) Announce Agreement to Commercialize TriCAR-T Cell Immunotherapy for Leukemia and Lymphoma PR Newswire

Immunoact lays groundwork for India cell, gene therapy innovation BioWorld MedTech

Cutting-edge CAR-T cancer therapy is now made in India — at one-tenth the cost Nature

India's 1st CAR-T cell therapy developed by ImmunoACT gets CDSCO nod Times of India

Foreign Secretary Ebrard announces the arrival in Mexico of a new cancer treatment Gob MX

Foreign Minister says CAR-T cell cancer therapy coming to Mexico Mexico News Daily

Mexico, India Sign Memorandum of Understanding on Immunotherapy Mexico Business News

President of India Launches India’s First Home-Grown Gene Therapy for Cancer developed by IIT Bombay, Tata Memorial Centre and ImmunoACT PIB

Sahyadri, ImmunoACT unveil CAR-T cell therapy Healthcare Radius

Laurus Labs buys additional stake in ImmunoACT for Rs 80 Cr BioSpectrum India

Laurus Labs acquires additional stake in ImmunoACT for Rs 80 crore CNBC TV18

Laurus funding will help make CAR-T therapy affordable in India: Rahul Purwar, ImmunoACT Moneycontrol

India launches Immunoact’s homegrown NexCAR19 for cancer BioWorld MedTech

Laurus Labs invests Rs 80 crore in cell & gene therapy firm ImmunoACT The Economic Times

IIT-B startup ImmunoACT's “affordable” blood cancer therapy gets regulatory approval - a first for India' Times of India

Max Healthcare launches CAR-T cell therapy in collaboration with ImmunoACT ET HealthWorld

Laurus Labs to acquire another 7.24% stake in ImmunoACT for Rs 80 crore Times of India

CDSCO approves ImmunoACT’s CAR-T cell therapy The Hindu

Sahyadri Hospitals, ImmunoACT collaborate to introduce CAR-T cell therapies in Pune ET HealthWorld

Laurus Labs further invests in gene therapy tech, increases its stake in lmmunoACT to 33.86% Business Today

Pune’s Sahyadri Hospitals partner with ImmunoACT for CAR-T cell therapy to treat certain forms of cancer The Indian Express

Sahyadri Hospitals and ImmunoACT partners to introduce advanced CAR-T cell therapies in Pune Pharmabiz.com

Laurus labs acquires 26.62 percent stake in ImmunoACT for Rs 46 crore Medical Dialogues

ImmunoACT gets CDSCO approval for India's first CAR-T cell therapy for blood cancer Moneycontrol

Laurus Labs to buy 26% stake in cell therapy firm ImmunoACT for ₹46 cr. The Hindu

Laurus Labs acquires 26.62% stake in ImmunoACT for Rs 46 crore Moneycontrol

ImmunoACT to lead journey of indigenous CAR-T cell therapy in India but market access a hurdle: GlobalData Express Pharma

Sahyadri Hospitals collaborates with ImmunoACT for Advanced CAR-T Cell Therapies Medical Dialogues

P. D. Hinduja Hospital collaborates with ImmunoACT to advance cancer care in Mumbai BioSpectrum India

ImmunoACT announces CDSCO approval of India’s first CAR-T cell therapy NexCAR19 BioSpectrum India

Hyderabad-based Laurus Labs to acquire minority stake in ImmunoACT Telangana Today

Groundbreaking News: Indian Startup’s Breakthrough Cancer Treatment Approved at Affordable Rates, Revolutionizing Access to Advanced Therapy BioTecNika

IIT Bombay’s ImmunoACT gets approval for first CAR-T cell therapy, says affordable for all Careers360

IIT Bombay's ImmunoACT Receives Approval For India’s First CAR-T Cell Therapy TimelineDaily